We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Syrris Atlas has the Midas Touch with Nanoparticles

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Syrris Atlas has the Midas Touch with Nanoparticles"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Midatech’s CEO, Justin Barry, explained: “Midatech is a clinical stage biotechnology company focused on translating its proprietarygold nanoparticle drug delivery platform into effective nanomedicines targeting currently unmet medical needs."

"We begin by producing functionalized gold nanoparticles on a bench scale, then move to larger scale manufacturing processes, where it makes sense to use a reactor system. Our Atlas Potassium reactors, with pH control and an Atlas Syringe Pump XL, have allowed us to scale¬up production, enabling variables such as pH and temperature to be tightly controlled.”

“The Atlas Potassium was the only logical way to move from manufacturing nanoparticles on a laboratory scale to a mini production environment. It is a reliable and reproducible reactor system that is well assembled, compact and portable, and performs exactly as we were told it would."

"Atlas Potassium is also very flexible, accommodating volumes ranging from 50 ml to 2 liters, and its operating software works well, enabling a series of validation runs to be performed quickly and easily. The Atlas reactors were easy to implement in the laboratory, and it took just six to eight months to establish a validated process. We are very happy with them.”